Journal of the National Cancer Center (Dec 2023)
Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)
- Bu Hong,
- Fan Ying,
- Fan Zhaoqing,
- Hu Xichun,
- Li Man,
- Li Qiao,
- Liao Ning,
- Luo Ting,
- Nie Jianyun,
- Pan Yueyin,
- Qi Xiaowei,
- Shao Zhimin,
- Song Guohong,
- Sun Tao,
- Teng Yue-e,
- Tong Zhongsheng,
- Wang Jiayu,
- Wang Shusen,
- Wang Xue,
- Wang Yongsheng,
- Wang Zhonghua,
- Xu Binghe,
- Xu Ling,
- Xue Yan,
- Yang Wentao,
- Yao Herui,
- Ying Jianming,
- Yuan Peng,
- Zhang Jian,
- Zhang Qingyuan,
- Zhang Yongqiang,
- Zhao Jiuda
Affiliations
- Bu Hong
- Department of Pathology, West China Hospital of Sichuan University, Chengdu, China
- Fan Ying
- Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Fan Zhaoqing
- Center for Prevention and Treatment of Breast Cancer, Peking University Cancer Hospital/Beijing Institute for Cancer Research, Beijing, China
- Hu Xichun
- Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Li Man
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, China
- Li Qiao
- Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Liao Ning
- Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, China
- Luo Ting
- Breast Disease Center, West China Hospital of Sichuan University, Chengdu, China
- Nie Jianyun
- The Third Department of Breast Cancer, Yunnan Cancer Hospital, Kunming, China
- Pan Yueyin
- Department of Oncology, The First Affiliated Hospital of USTC/Anhui Provincial Hospital, Hefei, China
- Qi Xiaowei
- Department of Breast and Thyroid Surgery, The Southwest Hospital of AMU, Chongqing, China
- Shao Zhimin
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Song Guohong
- Department of Breast Oncology, Peking University Cancer Hospital/Beijing Institute for Cancer Research, Beijing, China
- Sun Tao
- Department of Breast Medicine, Liaoning Cancer Hospital & Institute, Shenyang, China
- Teng Yue-e
- Department of Oncology, The First Hospital of China Medical University, Shenyang, China
- Tong Zhongsheng
- Department of Breast Medicine, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
- Wang Jiayu
- Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Wang Shusen
- Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Wang Xue
- Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Wang Yongsheng
- Breast Disease Center, Shandong Provincial Cancer Hospital Affiliated to Shandong University, Jinan, China
- Wang Zhonghua
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Xu Binghe
- Department of Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Corresponding authors.
- Xu Ling
- Breast Disease Center, Peking University First Hospital, Beijing, China
- Xue Yan
- Department of Oncology, Xi'an International Medical Center Hospital/Oncology Hospital, Xi'an, China
- Yang Wentao
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Yao Herui
- Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
- Ying Jianming
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Yuan Peng
- Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Corresponding authors.
- Zhang Jian
- Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Zhang Qingyuan
- Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China
- Zhang Yongqiang
- Department of Oncology, Beijing Hospital, Beijing, China
- Zhao Jiuda
- Center for Mastopathy Diagnosis and Treatment, Qinghai University Affiliated Hospital, Qinghai 810000, China
- Journal volume & issue
-
Vol. 3,
no. 4
pp. 266 – 272
Abstract
Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.
